Trajectories of microbiome-derived bile acids in early life – insights into the progression to islet autoimmunity

Competing Interest Statement

P.C.D. is an advisor and holds equity in Cybele and Sirenas, is a science advisor and holds equity in bileOmix and is a Scientific co-founder, advisor and holds equity to Ometa, Enveda, and Arome with prior approval by UC-San Diego. PCD also consulted for DSM animal health in 2023. The other authors declare no competing interests.

Funding Statement

This study was supported by the Inflammation in human early life targeting impacts on life course health (INITIALISE) consortium funded by the Horizon Europe Program of the European Union under Grant Agreement 101094099 (to M.O.), the Research Council of Finland funding (no. 363417 to S.L.), the Research council of Finland project grant (grant no. 333981 to M.O.), and the Novo Nordisk Foundation (grant no. NNF20OC0063971 to T.H. and M.O.). Further support was received from the Swedish Research Council (grant no. 2016.05176 to T.H. and M.O.), Formas (grant no. 2019.00869 to T.H. and M.O.), and the Medical Research Funds, Helsinki University Hospital (to M.K.). Further support was received by the InFLAMES Flagship Programme of the Academy of Finland (grant no. 337530). We further acknowledge support by NICHD, P50HD106463, and NIDDK R01DK136117, U24DK133658 (to P.C.D.). RJX funded by NIH (DK 43351, AI172147) and Center for Microbiome Informatics and Therapeutics. Mass spectrometeric analysis was performed at the Turku Metabolomics Centre with the support of Biocenter Finland. The DIABIMMUNE study was supported by the European Union Seventh Framework Programme FP7.2007.2013 under grant agreement number 202063 (to M.K.), Juvenile Diabetes Research Foundation grants 17.2011.529 and 17.2014.305 to R.L., and The Academy of Finland Centre of Excellence in Molecular Systems Immunology and Physiology Research grant Decision number 250114, 2012 to 2017 (to M.O. and M.K.).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was conducted according to the guidelines in the Declaration of Helsinki. All families provided written informed consent prior to sample collection.This study was approved by the Ethical Committee, Tampere University Hospital, Tampere, Finland (approval number R11166).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes